Get the Daily Brief
Latest Biotech News
Danaher shells out $10B for Masimo — diagnostics consolidation accelerates
Danaher announced a definitive agreement to acquire Masimo for approximately $10 billion in cash, expanding Danaher’s footprint in patient monitoring and diagnostics. The deal values Masimo at...
Guardant ramps screening business, buys MetaSight — Shield growth accelerated
Guardant Health projected material screening revenue growth for 2026 and disclosed the acquisition of MCED startup MetaSight Diagnostics for $59 million upfront (plus up to $90 million...
Altesa raises $75M to reboot antiviral vapendavir program
Altesa BioSciences closed a $75 million Series B to advance vapendavir, an antiviral targeting rhinovirus, into larger mid-stage trials focused on chronic lung disease populations. The financing...
Japan backs two iPSC therapies under conditional approval pathway
Japan’s regulatory advisory panel recommended conditional approvals for two induced pluripotent stem cell (iPSC)-derived products — Amchepry (raguneprocel) and Reheart — under the country’s...
Novartis to sell India unit — keeps R&D and commercial operations separate
Novartis will divest its 70.68% stake in Novartis India Limited to a private-equity consortium for about $159 million while retaining separate in-country commercial and R&D operations through...
Disordered lipid nanoparticles boost cargo release — delivery rethink
New research from the University of Copenhagen suggests that internal disorder within lipid nanoparticles (LNPs) improves intracellular release of RNA cargo. Using a high-throughput,...
Element unveils Vitari: $100 genome on 36‑hour runs
Element Biosciences introduced Vitari, its first high-throughput sequencing platform designed to generate 3 Tb per paired-end 150 bp run in 36 hours and to deliver a 30× human genome for roughly...
Grail's Galleri misses NHS goal — market rout follows
Grail reported that its large NHS-Galleri multicancer early detection trial failed to meet the study's primary endpoint of a statistically significant reduction in late-stage (Stage III–IV)...
FDA formalizes single‑trial default — NEJM perspective
Top FDA officials published a New England Journal of Medicine perspective formalizing a new default: one adequate and well‑controlled pivotal trial can serve as the basis for approval,...
FDA reverses Moderna refusal — review resumes
The FDA reversed a recent refusal‑to‑file decision and agreed to review Moderna’s mRNA seasonal flu vaccine after a Type A meeting between the company and regulators. The agency had initially...
Guardant buys MetaSight; Shield screening set to scale
Guardant Health acquired early cancer‑detection startup MetaSight Diagnostics for $59 million upfront plus up to $90 million in contingent payments, expanding its multiomics screening portfolio as...
Altesa raises $75M to advance vapendavir trials
Altesa BioSciences closed a $75 million Series B led by Forbion to advance vapendavir, an antiviral targeting rhinovirus, into larger trials for chronic lung disease. The financing — which...
Structures of bacterial RNR control point to new antibiotic strategies
Researchers mapped the structural mechanisms by which bacteria regulate ribonucleotide reductase (RNR) activity via the specialized transcriptional regulator NrdR, revealing bacterial‑specific...
Disorganized LNPs release RNA more efficiently — single‑particle study
A University of Copenhagen team reported that amorphous lipid nanoparticles (LNPs) release therapeutic cargo more efficiently than highly organized particles, based on a high‑throughput...
Functional electrophysiology probe aims to improve organoid screening
Diagnostic Biochips introduced a neural probe platform designed to record functional electrophysiology from brain organoids at scale, a capability the company says will improve early‑stage...
Element unveils Vitari — $100 30X genome in 36 hours
Element Biosciences launched Vitari, a high‑throughput sequencing platform the company says can deliver 3 terabases per paired‑end 150 bp run in 36 hours and sequence a 30X human genome for...
Stanford reports universal intranasal vaccine protecting mice across respiratory threats
Stanford Medicine reported a preclinical intranasal vaccine that protected mice against multiple respiratory viruses, bacterial pathogens and even an allergen by combining innate and adaptive...
Grail’s Galleri misses NHS goal — stock tumbles
Grail disclosed that its large NHS-Galleri multicancer early detection (MCED) trial failed to meet the study’s primary endpoint, triggering a sharp sell-off in the company’s shares. The trial, run...
FDA formalizes single pivotal-trial default — approval bar shifts
FDA leaders have signaled a formal shift: the agency will default to accepting one well-controlled, adequately run pivotal trial as sufficient evidence for approval, augmented by “confirmative...
Japan backs two iPSC therapies: first-in-world approvals near
Japan’s regulatory subcommittee recommended conditional, time-limited approvals for two induced pluripotent stem cell (iPSC)-derived therapies — Amchepry (raguneprocel) and Reheart — positioning...